ID 119010018
Alternative Names: ID-11901; ID-119010018; ID-11901GLLatest Information Update: 28 Jul 2024
At a glance
- Originator Ildong Pharmaceutical
- Class Antiglaucomas; Small molecules
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Glaucoma in South Korea
- 05 Jan 2022 Ildong Pharmaceutical announces intention to submit IND application for Glaucoma in first quarter of 2023 (Ildong pharmaceutical pipeline,
- 24 Jun 2020 ID 11901 is available for licensing as of 24 Jun 2020. https://www.ildong.com/